{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T09:50:03Z","timestamp":1695894603240},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Comput Assist Tomogr"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Immune checkpoint inhibitor therapy has revolutionized the treatment of many different types of cancer. However, despite dramatic improvements in tumor oncologic response and patient outcomes, immune checkpoint blockade has been associated with multiple distinctive side-effects termed immune-related adverse events. These often have important clinical implications because these can vary in severity, sometimes even resulting in death. Therefore, it is important for both radiologists and clinicians to recognize and be aware of these reactions to help appropriately guide patient management. This article specifically highlights imaging manifestations of the most common cardiothoracic toxicities of these agents, including pneumonitis, sarcoid-like granulomatosis and lymphadenopathy, and myocarditis.<\/jats:p>","DOI":"10.1097\/rct.0000000000001068","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T15:00:17Z","timestamp":1598367617000},"page":"652-655","source":"Crossref","is-referenced-by-count":2,"title":["Cardiothoracic Complications of Immune Checkpoint Inhibitor Therapy: An Imaging Review"],"prefix":"10.1097","volume":"44","author":[{"given":"Saurabh","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrance T.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"bib1-20230927","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7555\/JBR.31.20160168","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"32","year":"2018","journal-title":"J Biomed Res"},{"key":"bib2-20230927","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.2147\/OTT.S150817","article-title":"Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer","volume":"11","year":"2018","journal-title":"Onco Targets Ther"},{"key":"bib3-20230927","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"bib4-20230927","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib5-20230927","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib6-20230927","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor\u2013related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","year":"2016","journal-title":"JAMA Oncol"},{"key":"bib7-20230927","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 9","key":"bib8-20230927","first-page":"125","article-title":"459P - risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001","volume":"26","year":"2015","journal-title":"Ann Oncol"},{"key":"bib9-20230927","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-related pneumonitis during cancer immunotherapy","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib10-20230927","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/2326-6066.CIR-15-0267","article-title":"Anti-PD-1 inhibitor\u2013related pneumonitis in non-small cell lung cancer","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"bib11-20230927","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib12-20230927","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","year":"2017","journal-title":"Eur Respir J"},{"key":"bib13-20230927","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2217\/fon-2019-0102","article-title":"Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma","volume":"15","year":"2019","journal-title":"Future Oncol"},{"key":"bib14-20230927","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1002\/cam4.1579","article-title":"Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study","volume":"7","year":"2018","journal-title":"Cancer Med"},{"key":"bib15-20230927","first-page":"739","article-title":"Pneumonitis from anti-PD-1\/ PD-L1 therapy","volume":"31","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"bib16-20230927","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","year":"2018","journal-title":"J Immunother Cancer"},{"key":"bib17-20230927","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-018-0372-4","article-title":"Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment","volume":"6","year":"2018","journal-title":"J Immunother Cancer"},{"key":"bib18-20230927","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","year":"2016","journal-title":"Chest"},{"key":"bib19-20230927","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1148\/radiol.2018180572","article-title":"Pembrolizumab-induced sarcoid-like reactions during treatment of metastatic melanoma","volume":"289","year":"2018","journal-title":"Radiology"},{"key":"bib20-20230927","doi-asserted-by":"crossref","first-page":"e00542","DOI":"10.1002\/rcr2.542","article-title":"Durvalumab induced sarcoid-like pulmonary lymphadenopathy","volume":"8","year":"2020","journal-title":"Respirol Case Rep"},{"key":"bib21-20230927","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2217\/imt-2018-0035","article-title":"Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma","volume":"10","year":"2018","journal-title":"Immunotherapy"},{"key":"bib22-20230927","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1513\/AnnalsATS.201611-863LE","article-title":"Sarcoidosis-like granulomatous lung reaction associated with anti-programmed death receptor-1 ligand therapy","volume":"14","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"bib23-20230927","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1148\/radiol.2018181349","article-title":"Imaging of cancer immunotherapy: current approaches and future directions","volume":"290","year":"2019","journal-title":"Radiology"},{"key":"bib24-20230927","first-page":"138","article-title":"Pitfalls in the radiological response assessment of immunotherapy","volume":"11","year":"2018","journal-title":"Memory"},{"key":"bib25-20230927","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","year":"2017","journal-title":"J Immunother Cancer"},{"key":"bib26-20230927","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib27-20230927","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"bib28-20230927","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","year":"2018","journal-title":"Lancet"},{"key":"bib29-20230927","doi-asserted-by":"crossref","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"bib30-20230927","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","year":"2018","journal-title":"Oncologist"},{"key":"bib31-20230927","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib32-20230927","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","year":"2019","journal-title":"Cardiovasc Res"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T18:34:48Z","timestamp":1695839688000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000001068","relation":{},"ISSN":["1532-3145","0363-8715"],"issn-type":[{"value":"1532-3145","type":"electronic"},{"value":"0363-8715","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,25]]}}}